CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)
Jaguar Health's subsidiary Napo Pharmaceuticals recapped a panel at the 2nd Best of Elite Ped-GI meeting in Dubai, where its CSO and clinical investigators discussed pediatric intestinal failure and crofelemer. Panelists reviewed data from pediatric MVID and SBS-IF patients on liquid oral crofelemer for over a year, showing reduced parenteral support normalized to body weight and improved weight and stature growth parameters.
Key figures
- Drug Name
- crofelemer (liquid oral formulation / powder for oral solution)
- Dosing duration
- >1 year of liquid oral crofelemer in pediatric MVID and SBS-IF patients
- Nda filing target
- mid-2027
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.